Vir Biotechnology (VIR) EBIT Margin (2018 - 2026)
Vir Biotechnology's (VIR) quarterly EBIT Margin came in at 456172.41% in Q1 2026, down 45156994.0% year-on-year from N/an in Q1 2025, and down 609798.93% quarter-over-quarter from 74.79% in Q4 2025.
Vir Biotechnology (VIR) EBIT Margin (2018 - 2026) Analysis & Trends
Vir Biotechnology has disclosed EBIT Margin across 9 years of filings, most recently posting 456172.41% for Q1 2026.
- EBIT Margin for Q1 2026 came in at 456172.41%, down 45156994.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 720.14% (up 237958.0% YoY), and the FY2025 annual result was 699.18%, up 9210.0% from the prior year.
- EBIT Margin came in at 456172.41% for Q1 2026 at Vir Biotechnology, down from 74.79% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 82.26% in Q1 2022 to a low of 456172.41% in Q1 2026.
- The 5-year median for EBIT Margin is 946.74% (2024), against an average of 33727.91%.
- Across the five-year window, EBIT Margin surged 811025 bps in 2022 and sank 45156994 bps in 2026, its largest moves.
- Vir Biotechnology's EBIT Margin stood at 304.6% in 2022, then slumped by 172 bps to 828.12% in 2023, then decreased by 14 bps to 946.74% in 2024, then jumped by 92 bps to 74.79% in 2025, then sank by 609799 bps to 456172.41% in 2026.
- The last three EBIT Margin figures came in at 456172.41% (Q1 2026), 74.79% (Q4 2025), and 72267.92% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Vir Biotechnology | 1.27 Bn | 1.27 Bn | - | -456,172.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -456,172.41% |
| Dec 31, 2025 | -74.79% |
| Sep 30, 2025 | -72,267.92% |
| Jun 30, 2025 | -9,754.28% |
| Mar 31, 2025 | -4,602.47% |
| Dec 31, 2024 | -946.74% |
| Sep 30, 2024 | -9,718.66% |
| Jun 30, 2024 | -5,158.70% |
| Mar 31, 2024 | -154.90% |
| Dec 31, 2023 | -828.12% |
| Sep 30, 2023 | -7,075.86% |
| Jun 30, 2023 | -5,667.26% |
| Mar 31, 2023 | -227.73% |
| Dec 31, 2022 | -304.60% |
| Sep 30, 2022 | 52.05% |
| Jun 30, 2022 | -554.34% |
| Mar 31, 2022 | 82.26% |
| Dec 31, 2021 | 70.35% |
| Sep 30, 2021 | -51.52% |
| Jun 30, 2021 | 36.25% |